| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Amir Krivoy, Eromona Whiskey, Henrietta Webb-Wilson, Dan Joyce, Derek K Tracy, Fiona Gaughran, James H MacCabe, Sukhwinder S Shergil. Outcomes in treatment-resistant schizophrenia: symptoms, function and clozapine plasma concentrations. Therapeutic advances in psychopharmacology. vol 11. 2021-10-23. PMID:34676067. |
clozapine is the only medication licenced for treating patients with treatment-refractory schizophrenia. |
2021-10-23 |
2023-08-13 |
Not clear |
| Dan Siskind, Anthony W Russell, Shuichi Suetani, Dylan Flaws, Steve Kisely, Vikas Moudgil, Korinne Northwood, Gail Robinson, James G Scott, Terry Stedman, Nicola Warren, Karl Winckel, Peter Cosgrove, Andrea Bake. CoMET: a randomised controlled trial of co-commencement of metformin versus placebo as an adjunctive treatment to attenuate weight gain in patients with schizophrenia newly commenced on clozapine. Therapeutic advances in psychopharmacology. vol 11. 2021-10-22. PMID:34671454. |
comet: a randomised controlled trial of co-commencement of metformin versus placebo as an adjunctive treatment to attenuate weight gain in patients with schizophrenia newly commenced on clozapine. |
2021-10-22 |
2023-08-13 |
Not clear |
| F Williams, F Lenihan, A Row. Continuing clozapine treatment after a diagnosis of cardiomyopathy. Irish journal of psychological medicine. vol 38. issue 3. 2021-10-21. PMID:34465403. |
a patient in a medium secure psychiatric unit with a 19-year history of treatment-resistant schizophrenia and violence whose mental illness only responded to clozapine, was noted to have a sustained tachycardia. |
2021-10-21 |
2023-08-13 |
Not clear |
| Barbara Iruretagoyena, Carmen Paz Castañeda, Cristian Mena, Camila Diaz, Ruben Nachar, Juan Pablo Ramirez-Mahaluf, Alfonso González-Valderrama, Juan Undurraga, James H Maccabe, Nicolas A Crossle. Predictors of clozapine discontinuation at 2 years in treatment-resistant schizophrenia. Schizophrenia research. vol 235. 2021-10-19. PMID:34340062. |
predictors of clozapine discontinuation at 2 years in treatment-resistant schizophrenia. |
2021-10-19 |
2023-08-13 |
Not clear |
| Noraly Stam, Heidi Taipale, Antti Tanskanen, Luka Isphording, Cynthia Okhuijsen-Pfeifer, Catharina C M Schuiling-Veninga, Jens H J Bos, Bert J Bijker, Jari Tiihonen, Jurjen J Luyk. Persistence of Antipsychotic Use After Clozapine Discontinuation: A Real-World Study Across Antipsychotics. Clinical and translational science. vol 13. issue 6. 2021-10-15. PMID:32441836. |
although clozapine treatment is often discontinued due to limited efficacy or low tolerability, there is a lack of guidelines and evidence on treatment options after discontinuation of clozapine in patients with schizophrenia. |
2021-10-15 |
2023-08-13 |
human |
| Noraly Stam, Heidi Taipale, Antti Tanskanen, Luka Isphording, Cynthia Okhuijsen-Pfeifer, Catharina C M Schuiling-Veninga, Jens H J Bos, Bert J Bijker, Jari Tiihonen, Jurjen J Luyk. Persistence of Antipsychotic Use After Clozapine Discontinuation: A Real-World Study Across Antipsychotics. Clinical and translational science. vol 13. issue 6. 2021-10-15. PMID:32441836. |
registry data from a prescription database representative of the dutch population (1996-2017) was collected to investigate persistence in patients with schizophrenia who had been using clozapine for ≥ 90 days. |
2021-10-15 |
2023-08-13 |
human |
| Graham Blackman, Ebenezer Oloyede, Mark Horowitz, Robert Harland, David Taylor, James MacCabe, Philip McGuir. Reducing the Risk of Withdrawal Symptoms and Relapse Following Clozapine Discontinuation-Is It Feasible to Develop Evidence-Based Guidelines? Schizophrenia bulletin. 2021-10-15. PMID:34651184. |
clozapine is the only antipsychotic that is effective in treatment-resistant schizophrenia. |
2021-10-15 |
2023-08-13 |
Not clear |
| Mariana Fioramonte, Guilherme Reis-de-Oliveira, Caroline Brandão-Teles, Daniel Martins-de-Souz. A glimpse on the architecture of hnRNP C1/C2 interaction network in cultured oligodendrocytes. Biochimica et biophysica acta. Proteins and proteomics. vol 1869. issue 12. 2021-10-12. PMID:34403818. |
hnrnps were shown differentially regulated on schizophrenia postmortem brain tissue as well as in cultured oligodendrocytes treated with clozapine, a common antipsychotic used in schizophrenia treatment. |
2021-10-12 |
2023-08-13 |
Not clear |
| Basile Chrétien, Véronique Lelong-Boulouard, Sylvain Chantepie, Marion Sassier, Mickael Bertho, Perrine Brazo, Xavier Humbert, Joachim Alexandre, Sophie Fedrizzi, Charles Dolladill. Haematologic malignancies associated with clozapine Psychological medicine. vol 51. issue 9. 2021-10-11. PMID:32036793. |
haematologic malignancies associated with clozapine clozapine is mainly used in patients with treatment-resistant schizophrenia and may lead to potentially severe haematologic adverse events, such as agranulocytosis. |
2021-10-11 |
2023-08-13 |
Not clear |
| Elias Wagner, Spyridon Siafis, Piyumi Fernando, Peter Falkai, William G Honer, Astrid Röh, Dan Siskind, Stefan Leucht, Alkomiet Hasa. Efficacy and safety of clozapine in psychotic disorders-a systematic quantitative meta-review. Translational psychiatry. vol 11. issue 1. 2021-10-11. PMID:34552059. |
clozapine appears to have superior effects on positive, negative, and overall symptoms and relapse rates in schizophrenia (treatment-resistant and non-treatment-resistant subpopulations) compared to first-generation antipsychotics (fgas) and to pooled fgas/second-generation antipsychotics (sgas) in treatment-resistant schizophrenia (trs). |
2021-10-11 |
2023-08-13 |
Not clear |
| Elias Wagner, Spyridon Siafis, Piyumi Fernando, Peter Falkai, William G Honer, Astrid Röh, Dan Siskind, Stefan Leucht, Alkomiet Hasa. Efficacy and safety of clozapine in psychotic disorders-a systematic quantitative meta-review. Translational psychiatry. vol 11. issue 1. 2021-10-11. PMID:34552059. |
our meta-review outlines the superior overall efficacy of clozapine compared to fgas and most other sgas in schizophrenia and suggests beneficial efficacy outcomes in bipolar disorder and parkinson's disease psychosis (pdp). |
2021-10-11 |
2023-08-13 |
Not clear |
| Masataka Kikuchi, Takanobu Nakazawa, Makoto Kinoshita, Hidenaga Yamamori, Yuka Yasuda, Michiko Fujimoto, Ryota Hashimoto, Shusuke Numat. Methylation Analysis in Monozygotic Twins With Treatment-Resistant Schizophrenia and Discordant Responses to Clozapine. Frontiers in psychiatry. vol 12. 2021-10-08. PMID:34616320. |
methylation analysis in monozygotic twins with treatment-resistant schizophrenia and discordant responses to clozapine. |
2021-10-08 |
2023-08-13 |
Not clear |
| Masataka Kikuchi, Takanobu Nakazawa, Makoto Kinoshita, Hidenaga Yamamori, Yuka Yasuda, Michiko Fujimoto, Ryota Hashimoto, Shusuke Numat. Methylation Analysis in Monozygotic Twins With Treatment-Resistant Schizophrenia and Discordant Responses to Clozapine. Frontiers in psychiatry. vol 12. 2021-10-08. PMID:34616320. |
clozapine, an atypical antipsychotic, is a well-established therapy for treatment-resistant schizophrenia. |
2021-10-08 |
2023-08-13 |
Not clear |
| Masataka Kikuchi, Takanobu Nakazawa, Makoto Kinoshita, Hidenaga Yamamori, Yuka Yasuda, Michiko Fujimoto, Ryota Hashimoto, Shusuke Numat. Methylation Analysis in Monozygotic Twins With Treatment-Resistant Schizophrenia and Discordant Responses to Clozapine. Frontiers in psychiatry. vol 12. 2021-10-08. PMID:34616320. |
in this study, we focused on a set of monozygotic twins with treatment-resistant schizophrenia in which one twin effectively responded to clozapine treatment and the other did not. |
2021-10-08 |
2023-08-13 |
Not clear |
| Masataka Kikuchi, Takanobu Nakazawa, Makoto Kinoshita, Hidenaga Yamamori, Yuka Yasuda, Michiko Fujimoto, Ryota Hashimoto, Shusuke Numat. Methylation Analysis in Monozygotic Twins With Treatment-Resistant Schizophrenia and Discordant Responses to Clozapine. Frontiers in psychiatry. vol 12. 2021-10-08. PMID:34616320. |
these results suggest that effective clozapine action may correct the abnormalities of neuronal and synapse functions in schizophrenia via changes in methylation. |
2021-10-08 |
2023-08-13 |
Not clear |
| Seon-Cheol Park, Bong Ju Lee, Jae Hong Park, Hiroaki Kawasaki, Ajit Avasthi, Sandeep Grover, Andi J Tanra, Shih-Ku Lin, Afzal Javed, Chay Hoon Tan, Norman Sartorius, Naotaka Shinfuku, Yong Chon Par. QT interval prolongation noted in one percent of 2553 Asian patients with schizophrenia: Findings from the REAP-AP survey. The Kaohsiung journal of medical sciences. vol 36. issue 12. 2021-10-07. PMID:32772489. |
schizophrenia patients were characterized by lower proportions of disorganized speech and negative symptoms; higher use of amisulpride and clozapine; and higher proportions of rigidity, hypercholesterolemia, and sedation than those without qtc prolongation. |
2021-10-07 |
2023-08-13 |
Not clear |
| Seon-Cheol Park, Bong Ju Lee, Jae Hong Park, Hiroaki Kawasaki, Ajit Avasthi, Sandeep Grover, Andi J Tanra, Shih-Ku Lin, Afzal Javed, Chay Hoon Tan, Norman Sartorius, Naotaka Shinfuku, Yong Chon Par. QT interval prolongation noted in one percent of 2553 Asian patients with schizophrenia: Findings from the REAP-AP survey. The Kaohsiung journal of medical sciences. vol 36. issue 12. 2021-10-07. PMID:32772489. |
finally, a binary logistic mode showed that amisulpride, clozapine, rigidity, and hypercholesterolemia might be the distinctive clinical correlates of qtc prolongation in asian patients with schizophrenia. |
2021-10-07 |
2023-08-13 |
Not clear |
| Seon-Cheol Park, Bong Ju Lee, Jae Hong Park, Hiroaki Kawasaki, Ajit Avasthi, Sandeep Grover, Andi J Tanra, Shih-Ku Lin, Afzal Javed, Chay Hoon Tan, Norman Sartorius, Naotaka Shinfuku, Yong Chon Par. QT interval prolongation noted in one percent of 2553 Asian patients with schizophrenia: Findings from the REAP-AP survey. The Kaohsiung journal of medical sciences. vol 36. issue 12. 2021-10-07. PMID:32772489. |
these findings indicate the clinical implications that the uses of amisulpride and clozapine and the occurrences of rigidity and hypercholesterolemia may be potential risk factors for qtc prolongation of schizophrenia patients. |
2021-10-07 |
2023-08-13 |
Not clear |
| Edouard-Jules Laforgue, Marion Istvan, Marylène Guerlais, Anicet Chaslerie, Pascal Artarit, Genevieve Vallot, Pascale Jolliet, Marie Grall-Bronnec, Caroline Victorri-Vignea. What about regular hematological monitoring during clozapine treatment? A compliance analysis using the French health insurance database. Expert opinion on drug safety. vol 20. issue 10. 2021-10-07. PMID:34085879. |
the aim of this study was to assess the compliance with wbcm during clozapine initiation for schizophrenia and parkinson's disease (pd) subjects. |
2021-10-07 |
2023-08-13 |
human |
| Francesco Monteleone, Márcia Gonçalves, Luís Fonseca, Sónia Simões, Andreia Gonçalves, Eduarda Machado, João Fonsec. Clozapine-Induced Eosinophilia: a Case Report. Revista Colombiana de psiquiatria (English ed.). 2021-10-07. PMID:34167790. |
clozapine is an atypical antipsychotic drug eligible for treatment-resistant schizophrenia. |
2021-10-07 |
2023-08-13 |
Not clear |